



Patients improving weight AND HbA1c in previous audits

Figure 5. Scatterplot of HbA_{1c} change and initial body weight change at 20-32 weeks of 1882 patients treated with **exenatide**



Dotted line indicates criteria of $\geq 1\%$ HbA_{1c} reduction and $\geq 3\%$ IBW reduction require by NICE for continuation of therapy – while 60.1% of patients achieved both HbA_{1c} and weight reduction, only 28.6% achieved this to the criteria level set by NICE.

Figure 6. Scatterplot of HbA_{1c} change and initial body weight change at 20-32 weeks of 1023 patients treated with **liraglutide**



Dotted line indicates criteria of $\geq 1\%$ HbA_{1c} reduction and $\geq 3\%$ IBW reduction require by NICE for continuation of therapy – while 59.3% of patients achieved both HbA_{1c} and weight reduction, only 25.0% achieved this to the criteria level set by NICE.

Changes in HbA_{1c} vs body weight by baseline

diabetes duration

